斯丹赛生物实体瘤CAR-T技术被评价为"新一代"癌症疗法，将重塑肿瘤治疗格局

Core Insights - The editorial "A Decade of JAMA Oncology" highlights significant advancements in cancer treatment over the past decade and anticipates disruptive future therapies, with Shanghai Stansai Biotech's GCC19CART cell therapy being recognized as a promising new generation cancer treatment [1][5]. Company Overview - Stansai Biotech is a clinical-stage biotechnology company focused on developing CAR-T cell therapy products for solid tumors, utilizing its proprietary CoupledCAR platform technology to address key challenges in solid tumor treatment [6][7]. Clinical Research Findings - The clinical study published in JAMA Oncology reported unprecedented objective response rates (ORR) and safety for GCC19CART in treating advanced metastatic colorectal cancer (mCRC), achieving a 57% ORR and a median overall survival (mOS) of 26.1 months at a dosage of 2X10^6 CAR-T cells per kilogram [3][4]. - Among responding patients, approximately 75% remained alive two years post-treatment, demonstrating the therapy's potential as a standalone treatment without combination with other drugs [3]. Technological Advancements - The CoupledCAR platform technology developed by Stansai Biotech enables CAR-T cells to self-expand, self-activate, and migrate effectively without antigen stimulation, significantly enhancing their activity and durability in solid tumor treatments [4]. Future Development Plans - Stansai Biotech aims to advance the global clinical development of GCC19CART and expand the application of the CoupledCAR platform technology to other solid tumors, including prostate and pancreatic cancers, striving to make effective, safe, and affordable cell therapies accessible to patients [5].